InvestorsHub Logo
Followers 834
Posts 120253
Boards Moderated 18
Alias Born 09/05/2002

Re: tika1 post# 2812

Friday, 12/22/2023 10:22:06 AM

Friday, December 22, 2023 10:22:06 AM

Post# of 3059
ALVR’s failed program was not for COVID:

https://www.globenewswire.com/news-release/2023/12/22/2800535/0/en/AlloVir-Provides-Updates-on-Phase-3-Clinical-Development-Program-for-Posoleucel-an-Allogeneic-Virus-Specific-T-Cell-Therapy.html

…posoleucel, an investigational off-the-shelf multi-virus-specific T cell therapy, which targets six viral pathogens in immunocompromised individuals: adenovirus (AdV), BK virus (BKV), cytomegalovirus (CMV), Epstein-Barr virus (EBV), human herpesvirus-6 (HHV-6) and JC virus (JCV).


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ENTA News